89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. 89bio, Inc. is one of them.

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardiometabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, pegozafermin, is a long-acting FGF21 analog designed to treat moderate to severe MASH, including advanced fibrosis, as well as related metabolic disorders.

In September 2025, Roche announced a definitive agreement to acquire 89bio, Inc. (NASDAQ:ETNB) for $14.50 per share in cash, valuing the company at approximately $2.4 billion. Shareholders will also receive a non-tradeable contingent value right (CVR) potentially worth up to $6 per share based on pegozafermin’s commercial success, bringing the total deal value to roughly $3.5 billion. This acquisition reflects strong confidence in pegozafermin’s potential as a best-in-class therapy for MASH, a serious liver condition often associated with obesity, and positions ETNB among the best performing stocks in the biotech sector.

Roche plans to integrate pegozafermin into its cardiovascular, renal, and metabolic portfolio, leveraging global development, manufacturing, and commercialization capabilities to maximize the therapy’s impact. The transaction is expected to close in Q4 2025 following unanimous board approval from both companies.

While we acknowledge the potential of ETNB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.